-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kain Technology announced that it has formally reached a strategic agreement with Wanbang Pharmaceutical.
In the future, the two parties will carry out in-depth cooperation in the fields of respiratory, rheumatism and other diseases, so as to realize the complementary advantages of both parties, create value together, and bring high-quality drugs to more patients.
Gospel
.
Specifically, according to the agreement, the strategic cooperation between the two parties will start with the exclusive promotion of Ambrox® (pirfenidone tablets)
.
According to the data, Ambrox® is a drug for the treatment of rare disease idiopathic pulmonary fibrosis (IPF), which can prolong the disease-free time of patients with IPF, slow down the decline of lung function, and improve the quality of life of patients
.
The industry believes that relying on Wanbang's professional commercialization platform and mature commercialization capabilities in the fields of respiratory and rheumatic diseases, Ambrose® products will reach the market more efficiently
.
In fact, in recent years, the "marriage" of cooperation between pharmaceutical companies has already become the norm
.
But it is worth noting that this year, this situation is becoming more and more frequent
.
For example, there are more and more phenomena such as local pharmaceutical companies pre-innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and cooperation between large and small companies, and the amount of cooperation involved is also increasing
.
For example, on the 18th, Shanghai Heyu Pharmaceutical announced that it had reached a global cooperation and exclusive license agreement with Eli Lilly.
innovative treatments in the field
.
It is understood that the cooperation project between Heyu Pharma and Eli Lilly has reached a milestone payment of 258 million US dollars and started from the early stage of drug development
.
In this regard, the analysis believes that this fully reflects the strong R&D strength of Heyu Pharma and Eli Lilly's recognition of the value of Heyu Pharma
.
At the same time, it also represents the confidence of both parties in the market space of indications covered by this target in the future
.
On the 11th, Fosun Pharma and Insilico Medicine also announced a cooperation agreement to jointly promote the research and development of AI drugs for multiple targets worldwide.
Insilico Medicine will receive an initial payment of US$13 million and milestone payments.
.
In addition to AI-driven drug R&D cooperation, Fosun Pharma will provide equity investment to Insilicon
.
It is understood that the US$13 million is currently a research and development cooperation project with a relatively high advance payment for AI pharmaceuticals in China
.
In addition to the above companies, a large number of domestic and foreign companies have announced plans to cooperate with other companies since the beginning of this year
.
Among them, Pfizer is particularly worth mentioning, which announced a number of important cooperations one after another from the 10th to the 11th, including the introduction of a number of technologies to supplement the product pipeline, and the use of AI technology to promote the development of anti-cancer drugs and other drugs etc.
_ Specifically, PostEra, a biotechnology company focusing on machine learning in the field of preclinical drug development, announced on the 11th that it will expand its existing strategic cooperation with Pfizer
.
The expanded multi-objective research program will establish an AI lab where PostEra and Pfizer will jointly advance multiple drug discovery programs
.
On the same day, Dren Bio also announced a partnership with Pfizer to focus on the development of bispecific antibodies
.
Under the terms of the agreement, Pfizer will pay Dren Bio an upfront payment of $25 million, and Dren Bio will be eligible to receive future development, regulatory and commercial milestone payments totaling more than $1 billion, as well as tiered royalties on future net product sales usage fee
.
On the 10th, Pfizer and Beam Therapeutics entered into an exclusive four-year research collaboration focused on in vivo base editing projects in rare genetic diseases such as the liver, muscle and central nervous system
.
In addition, a development and option agreement with Acuitas Therapeutics was announced, giving Pfizer the option to acquire Acuitas' LNP technology on a non-exclusive basis for the development of vaccines or therapeutic products for up to 10 targets
.
In the future, the two parties will carry out in-depth cooperation in the fields of respiratory, rheumatism and other diseases, so as to realize the complementary advantages of both parties, create value together, and bring high-quality drugs to more patients.
Gospel
.
Specifically, according to the agreement, the strategic cooperation between the two parties will start with the exclusive promotion of Ambrox® (pirfenidone tablets)
.
According to the data, Ambrox® is a drug for the treatment of rare disease idiopathic pulmonary fibrosis (IPF), which can prolong the disease-free time of patients with IPF, slow down the decline of lung function, and improve the quality of life of patients
.
The industry believes that relying on Wanbang's professional commercialization platform and mature commercialization capabilities in the fields of respiratory and rheumatic diseases, Ambrose® products will reach the market more efficiently
.
In fact, in recent years, the "marriage" of cooperation between pharmaceutical companies has already become the norm
.
But it is worth noting that this year, this situation is becoming more and more frequent
.
For example, there are more and more phenomena such as local pharmaceutical companies pre-innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and cooperation between large and small companies, and the amount of cooperation involved is also increasing
.
For example, on the 18th, Shanghai Heyu Pharmaceutical announced that it had reached a global cooperation and exclusive license agreement with Eli Lilly.
innovative treatments in the field
.
It is understood that the cooperation project between Heyu Pharma and Eli Lilly has reached a milestone payment of 258 million US dollars and started from the early stage of drug development
.
In this regard, the analysis believes that this fully reflects the strong R&D strength of Heyu Pharma and Eli Lilly's recognition of the value of Heyu Pharma
.
At the same time, it also represents the confidence of both parties in the market space of indications covered by this target in the future
.
On the 11th, Fosun Pharma and Insilico Medicine also announced a cooperation agreement to jointly promote the research and development of AI drugs for multiple targets worldwide.
Insilico Medicine will receive an initial payment of US$13 million and milestone payments.
.
In addition to AI-driven drug R&D cooperation, Fosun Pharma will provide equity investment to Insilicon
.
It is understood that the US$13 million is currently a research and development cooperation project with a relatively high advance payment for AI pharmaceuticals in China
.
In addition to the above companies, a large number of domestic and foreign companies have announced plans to cooperate with other companies since the beginning of this year
.
Among them, Pfizer is particularly worth mentioning, which announced a number of important cooperations one after another from the 10th to the 11th, including the introduction of a number of technologies to supplement the product pipeline, and the use of AI technology to promote the development of anti-cancer drugs and other drugs etc.
_ Specifically, PostEra, a biotechnology company focusing on machine learning in the field of preclinical drug development, announced on the 11th that it will expand its existing strategic cooperation with Pfizer
.
The expanded multi-objective research program will establish an AI lab where PostEra and Pfizer will jointly advance multiple drug discovery programs
.
On the same day, Dren Bio also announced a partnership with Pfizer to focus on the development of bispecific antibodies
.
Under the terms of the agreement, Pfizer will pay Dren Bio an upfront payment of $25 million, and Dren Bio will be eligible to receive future development, regulatory and commercial milestone payments totaling more than $1 billion, as well as tiered royalties on future net product sales usage fee
.
On the 10th, Pfizer and Beam Therapeutics entered into an exclusive four-year research collaboration focused on in vivo base editing projects in rare genetic diseases such as the liver, muscle and central nervous system
.
In addition, a development and option agreement with Acuitas Therapeutics was announced, giving Pfizer the option to acquire Acuitas' LNP technology on a non-exclusive basis for the development of vaccines or therapeutic products for up to 10 targets
.
